Beta Bionics (BBNX) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Beta Bionics.

Analyst Coverage

Research analysts who have asked questions during Beta Bionics earnings calls.

Brooks O'Neil

Lake Street Capital Markets

2 questions for BBNX

Also covers: ARAY, ATEC, DYNT +11 more

Mathew Blackman

Stifel

2 questions for BBNX

Also covers: AHCO, ATEC, CERS +7 more

Matthew O'Brien

Piper Sandler & Co.

2 questions for BBNX

Also covers: APYX, ATEC, ATRC +18 more

Michael Kratky

Leerink Partners

2 questions for BBNX

Also covers: AXGN, DXCM, INSP +6 more

Travis Steed

Bank of America

2 questions for BBNX

Also covers: ABT, AXNX, BAX +19 more

Felipe Lamar

Truist Securities

1 question for BBNX

Also covers: SIBN, TMCI, TNDM +1 more

Frank Takkinen

Lake Street Capital Markets

1 question for BBNX

Also covers: ANGO, AORT, AXGN +17 more

Jeffrey Johnson

Robert W. Baird & Co. Inc.

1 question for BBNX

Also covers: ALC, ALGN, COO +11 more

Jonathan Jeff

Baird

1 question for BBNX

Kelly Close

Close Concerns

1 question for BBNX

Matt O'Brien

Piper Sandler Companies

1 question for BBNX

Also covers: BSX, DXCM, GMED +6 more

Mike Polark

Wolfe Research, LLC

1 question for BBNX

Also covers: BSX, DXCM, EMBC +6 more

Philip Coover

Goldman Sachs

1 question for BBNX

Also covers: TNDM

Stephanie Piazzola

Bank of America

1 question for BBNX

Also covers: CBLL, KMTS, NARI +1 more

Latest news

Recent press releases and 8-K filings for BBNX.

Beta Bionics Announces Preliminary Q4 2025 Topline Results

BBNX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Beta Bionics (BBNX) reported preliminary, unaudited fourth quarter 2025 results, with net sales expected to be at least $32.0 million, an increase of at least 56% compared to the fourth quarter of 2024.
The company anticipates its installed customer base to grow by at least 128% to 35,000 users, and new patient starts to reach at least 5,581, up at least 36% from the fourth quarter of 2024.
Sales growth was notably strong in the Pharmacy Benefit Plan (PBP) channel, which is expected to generate at least $9.7 million, representing an increase of at least 308% compared to the fourth quarter of 2024.

Jan 8, 2026, 9:08 PM

8-K

Beta Bionics Announces Preliminary Q4 2025 Results

BBNX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Beta Bionics reported preliminary, unaudited topline financial results for the fourth quarter ended December 31, 2025.
Net sales are expected to be at least $32.0 million, an increase of at least 56% compared to $20.4 million in the fourth quarter of 2024.
The installed customer base is projected to reach at least 35,000 users, marking an increase of at least 128% from 15,298 in the fourth quarter of 2024.
New patient starts are anticipated to be at least 5,581, representing an increase of at least 36% compared to 4,084 new patient starts in the fourth quarter of 2024.
Pharmacy Benefit Plan (PBP) channel net sales are expected to be at least $9.7 million, up at least 308% compared to $2.4 million in the fourth quarter of 2024.

Jan 8, 2026, 9:04 PM

Press Release

Beta Bionics Discusses Strong Q3 Performance, iLet Adoption, and Accelerated PatchPump Development

BBNX

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Beta Bionics reported exceptionally good Q3 results and strong market adoption of its iLet product, with its sales force demonstrating high productivity despite being smaller than competitors.
The iLet algorithm's simplicity and effectiveness are resonating, attracting 70% of patients from MDI and over 25% from Type 2 diabetes, with approximately 50% of the patient population achieving an A1c under 7%.
The company saw notable pharmacy channel uptake in Q3, almost doubling the number of patients through this channel compared to Q2, with no pricing degradation.
Beta Bionics initiated its PatchPump project in December 2023, anticipating FDA approval in 2026 and an unconstrained launch by the end of 2027, leveraging its existing algorithm for faster development.
The company is committed to achieving profitability significantly faster than traditional industry timelines.

Dec 2, 2025, 9:30 PM

Transcript

Beta Bionics Discusses Strong Q3, iLet Adoption, and PatchPump Development

BBNX

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Beta Bionics reported exceptionally good Q3 results and is seeing strong market adoption of its iLet product, with a smaller sales force demonstrating high productivity.
The iLet algorithm is resonating due to its simplicity and effectiveness, achieving "quite good outcomes without a lot of work" and a 2.2% A1c reduction for unengaged patients, with approximately 50% of its population under 7 A1c.
The company has seen significant success in the pharmacy channel, doubling the number of patients through this channel in Q3 compared to Q2, and expects it to become a major tailwind when patients in the channel reach three times the quarterly additions.
Beta Bionics initiated its PatchPump project in December 2023, with anticipated approval "sometime next year" (2026) and a broader release in 2027, focusing on an ACE pump approval and simplified user experience.

Dec 2, 2025, 9:30 PM

Transcript

Beta Bionics Discusses iLet Adoption, Pharmacy Channel Growth, and PatchPump Development

BBNX

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Beta Bionics reported exceptionally good Q3 results for its iLet product, noting strong market adoption with 70% of patients coming from MDI and over 25% from Type 2.
The iLet algorithm demonstrates significant clinical effectiveness, with approximately 50% of the patient population achieving an A1c under 7% and a median A1c drop of 2.2% for less engaged patients.
The company saw a notable increase in Q3 pharmacy channel uptake, nearly doubling patients through this channel compared to Q2, establishing it as a competitive advantage.
Beta Bionics' PatchPump project, initiated in December 2023, is on track for approval next year and an unconstrained launch in 2027, utilizing their existing algorithm and pump development expertise.

Dec 2, 2025, 9:30 PM

Transcript

Beta Bionics Discusses Commercial Success, Patch Pump Development, and Regulatory Remediation

BBNX

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

Beta Bionics is experiencing commercial success, with accelerating growth in patient starts and revenue, driven by its product design and algorithm differentiation.
Pharmacy reimbursement has exceeded expectations, generating approximately $450 a month in recurring revenue per patient and proving more financially accretive in the medium and long term.
The company estimates it is capturing roughly 11% of all new patient starts in the US, despite its salesforce being half to a third the size of competitors.
Beta Bionics is targeting commercialization of its patch pump by the end of calendar year 2027, which will be pharmacy only and leverages existing pharmacy reimbursement agreements.
The company is remediating approximately 34,000 cases related to a difference in interpretation of reportable complaints, a process expected to conclude by June 2026.

Nov 18, 2025, 7:00 PM

Transcript

Beta Bionics Discusses Commercial Success, Patch Pump Development, and FDA Remediation

BBNX

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

Beta Bionics is experiencing commercial success, with patient starts and revenue growing at accelerating rates, attributing this to the iLet's differentiated design and algorithm.
Pharmacy reimbursement for the iLet has surpassed expectations, driving an increase in new patient starts by simplifying prescriptions for doctors and reducing patient out-of-pocket expenses, generating approximately $450 per month in recurring revenue.
The company estimates it is capturing approximately 11% of all new patient starts in the US within a competitive market.
Beta Bionics aims for commercialization of a patch pump by the end of calendar year 2027, with manufacturing already in progress and plans for it to be pharmacy-only, leveraging existing PBM agreements.
Remediation for approximately 34,000 cases related to FDA 483 observations on reportable complaints is projected to run from November through June of 2026, which will lead to a significant increase in reported complaints during this timeframe.

Nov 18, 2025, 7:00 PM

Transcript

Beta Bionics Discusses Commercial Success, Patch Pump Development, and FDA Remediation

BBNX

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

Beta Bionics is experiencing accelerating growth in new patient starts and revenue, largely due to better-than-expected pharmacy reimbursement, which is financially accretive and eases patient access.
The company estimates it captures approximately 11% of all new patient starts in the U.S. and plans to expand its sales force from 63 to approximately 120 territories.
Beta Bionics is targeting commercialization of a new pharmacy-only patch pump by the end of 2027, leveraging existing payer relationships to secure reimbursement.
An FDA remediation effort for 34,000 complaint cases is underway from November 2025 through June 2026, which will lead to a substantial increase in reported complaints in the MAUDE database during this period.

Nov 18, 2025, 7:00 PM

Transcript

Beta Bionics Reports Strong Q3 2025 Results and Raises Full-Year Guidance

BBNX

Earnings

Guidance Update

Product Launch

Beta Bionics reported strong Q3 2025 financial results, with net sales of $27.3 million, a 63% year-over-year increase, and 5,334 new patient starts, up 68% year-over-year.
The company achieved a gross margin of 55.5% in Q3 2025, an increase from 53.4% in Q3 2024, driven by increased scale and higher-margin pharmacy revenue.
Beta Bionics raised its full-year 2025 guidance, now expecting total revenue to be greater than $96.5 million (previously $88-$93 million) and gross margin between 54% and 55% (previously 52%-55%).
Adoption through the pharmacy channel continues to accelerate, with low 30s % of new patient starts in Q3 2025 utilizing this channel, significantly up from high single-digits in Q3 2024.
Progress was noted in the product pipeline, including the Mint patch pump on track for commercialization by the end of 2027, and the completion of a PK/PD trial for the biohormonal system's glucagon asset.

Oct 28, 2025, 8:30 PM

Transcript

Beta Bionics Reports Q3 2025 Earnings and Updates Full Year Guidance

BBNX

Earnings

Guidance Update

Product Launch

Beta Bionics reported Q3 2025 revenue of $27 million and a gross margin of 55%.
New patient starts totaled 5,334 in Q3 2025, with a low 30s% reimbursed through pharmacy.
The company updated its full-year 2025 guidance, now projecting total revenue greater than $96.5 million, new patient starts through pharmacy between 27-29%, and a gross margin of 54-55%.
Strategic highlights include effective formulary agreements with all major PBMs in July 2025 and iLet Special 510(k) Clearance for usability improvements in September 2025.